Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Musculoskeletal | Neurology | Family Medicine
Search Medical Condition
Multiple Sclerosis Clinical Trials
A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (406) clinical trials
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.
A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis
Subjects with RRMS who have experienced a relapse and who will receive 3 to 5 (given over a period of up to 7 days) days of treatment with high dose steroids (oral or IV) within 10 days of the onset of relapse symptoms are candidates for the current study. At ...
A research study for patients who have been diagnosed with multiple sclerosis
Study Purpose: This is an observational study in men and women (patients >18 years old) who have been diagnosed with multiple sclerosis. The purpose of this study is to better characterize the long-term benefits and risks of dimethyl fumarate (DMF) medication in patients with multiple sclerosis (MS) who are prescribed ...
A research study for patients who have been diagnosed with multiple sclerosis
The purpose of this study is to monitor the safety profile of an approved medication called fingolimod compared to other approved medications for the treatment of multiple sclerosis. This is a mulitnational study which will include approximately 2400 patients. It is an observational study of patients who will be starting ...
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis PASS – OBS13434
The proposed study utilizes a prospective, non-interventional, observational cohort study design to evaluate the necessary duration of monitoring following treatment with LEMTRADA and to further inform appropriate monitoring conditions. It will evaluate the long term safety profile, particularly the AESI incidence rates over time in RMS patients, to accomplish the ...
A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA® Treatment In Patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modifying Therapy
6.1 PRIMARY The primary objective of the study is to evaluate treatment satisfaction as the primary Patient- Reported Outcome (PRO) in patients with relapsing forms of MS (RMS) treated with LEMTRADA in a real life setting using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4. 6.2 SECONDARY The secondary ...
A study of rHIgM22 dosage in relapsing MS patients.
The purpose of this study is to measure safe and tolerable doses of rHIgM22 in patients with MS immediately following a relapse.
Clinical trial studying the effects of RPC1063 in RMS
The purpose of this study is to characterize the full pharmacokinetic and pharmacodynamics profiles of RPC1063 in patients with relapsing multiple sclerosis (RMS).
OBS14379-A prospective observational cohort study in adult patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA® (alemtuzumab) infusions of the first treatment course
Multiple sclerosis (MS) is a chronic and often disabling disorder of the central nervous system involving damage to the brain, optic nerves and spinal cord. Most patients initially present with relapsing remitting MS, experiencing unpredictable episodes of transient neurological deterioration (relapse) followed by a variable period of recovery (remission) during ...
A Multicenter, Double-Blind, Placebo-Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving TECFIDERA® (Dimethyl Fumarate) Delayed-Release Capsules
The primary objective of this study is to evaluate whether montelukast can reduce the severity of GI events after oral administration of DMF in subjects with relapsing forms of MS.
